Cost-effectiveness analysis of umeclidinium bromide/vilanterol 62.5/25 mcg versus tiotropium/olodaterol 5/5 mcg in symptomatic patients with chronic obstructive pulmonary disease: a Spanish National Healthcare System perspective. [electronic resource]
Producer: 20190225Description: 224 p. digitalISSN:- 1465-993X
- Aged
- Benzoxazines -- administration & dosage
- Benzyl Alcohols -- administration & dosage
- Chlorobenzenes -- administration & dosage
- Cost-Benefit Analysis -- methods
- Cross-Over Studies
- Drug Combinations
- Female
- Humans
- Male
- Middle Aged
- National Health Programs -- economics
- Prospective Studies
- Pulmonary Disease, Chronic Obstructive -- drug therapy
- Quinuclidines -- administration & dosage
- Single-Blind Method
- Spain -- epidemiology
- Tiotropium Bromide -- administration & dosage
No physical items for this record
Publication Type: Journal Article; Observational Study; Randomized Controlled Trial
There are no comments on this title.
Log in to your account to post a comment.